Harnessing the Human Immune System
for human-derived therapeutics against viral and bacterial infections, and cancer
Our Therapeutic Candidates
We have discovered five human monoclonal antibody (mAbs) therapies against bacterial, viral and cancer indications.
In vivo and in vitro experimental data show our antibodies possess superior binding affinity, broad-spectrum capabilities, and efficacy compared to alternative therapies
We are business leaders and scientists passionate about developing human antibody therapies to various diseases.
Our team offers diverse academic and operational expertise, covering all stages of drug development:
2) Preclinical Development
3) Clinical Trials